$460 Million is the total value of Broadfin Capital, LLC's 39 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVLNF | Exit | NOVELION THERAPEUTICS INC | $0 | – | -729,301 | -100.0% | -0.18% | – |
| OSMT | Exit | OSMOTICA PHARMACEUTICALS PLC | $0 | – | -307,854 | -100.0% | -0.23% | – |
| OPNT | Exit | OPIANT PHARMACEUTICALS INC | $0 | – | -85,484 | -100.0% | -0.23% | – |
| ATEC | Exit | ALPHATEC HOLDINGS INC | $0 | – | -442,966 | -100.0% | -0.24% | – |
| TLGT | Exit | TELIGENT INC NEW | $0 | – | -1,990,983 | -100.0% | -0.48% | – |
| NEOS | Exit | NEOS THERAPEUTICS INC | $0 | – | -1,611,999 | -100.0% | -0.87% | – |
| LIVN | Exit | LIVANOVA PLC | $0 | – | -48,000 | -100.0% | -0.96% | – |
| IART | Exit | INTEGRA LIFESCIENCES HLDGS C | $0 | – | -141,572 | -100.0% | -1.63% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -4,829,832 | -100.0% | -1.70% | – |
| XENT | Exit | INTERSECT ENT INC | $0 | – | -263,500 | -100.0% | -1.75% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -148,100 | -100.0% | -2.24% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -2,030,925 | -100.0% | -2.51% | – |
| MYGN | Exit | MYRIAD GENETICS INCcall | $0 | – | -500,000 | -100.0% | -3.43% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.